Liposome drug delivery system for murine neuroblastoma

• Published in: Journal of pediatric surgery Vol. 33; no. 10; pp. 1521 - 1525
• Main Authors: Nagae, Itsuro, Koyanagi, Yasuhisa, Ito, Shinichi, Tanabe, Yoshihide, Unezaki, Sakae
• Format: Journal Article
• Language: English
• Published: Philadelphia, PA Elsevier Inc 01-10-1998; Elsevier
• Subjects: Animals; Antibiotics, Antineoplastic - administration & dosage; Antineoplastic agents; Antineoplastic Agents - administration & dosage; Biological and medical sciences; Chemotherapy; Doxorubicin - administration & dosage; Drug Carriers; Female; Liposomes; Medical sciences; Mice; Mice, Inbred A; Neuroblastoma - drug therapy; Neuroblastoma - pathology; Pharmacology. Drug treatments; Tumor Cells, Cultured; liposomes; polyethyleneglycol; Neuroblastoma; Antineoplastic agent; Nervous system diseases; Drug combination; Pharmaceutical technology; Toxicity; Rodentia; Liposome; Tolerance; Malignant tumor; Doxorubicin; System; Chemotherapy; Vertebrata; Mammalia; Treatment; Mouse; Animal; Application method; Anthracyclins; Autonomic neuropathy
• ISSN: 0022-3468; 1531-5037
• DOI: 10.1016/S0022-3468(98)90489-4

Purpose:
The effects of liposome-infused doxorubicin on C-1300 murine neuroblastoma were studied. The liposome surface was covered with polyethylene glycol to avoid migration toward the reticuloendothelial system and to prolong its presence in the bloodstream. Liposome-infused doxorubicin hydrochloride (DXR), an anthracycline was used as an anticancer antibiotic substance.
Methods:
Each
A
J
mouse was transplanted with 1 × 10
5 C-1300 murine neuroblastoma cells subcutaneously in the thigh. The experiment was conducted when the maximum tumor dimension was 1 cm. The control group was given only physiological saline solutions, the second group was given DXR alone, and the third group received liposomeinfused DXR (Lip-DXR). The survival and doubling times were measured. One, 12, and 24 hours after the injection the DXR concentration in the cardiac tissues was measured for statistical comparison.
Results:
The survival time of the mice was found to be 27 ± 5.10 days in the control group, 31.40 ± 3.15 days in the DXR group, and 43.86 ± 2.13 days in the Lip-DXR group. The Lip-DXR group showed the longest survival time. The tumordoubling time was found to be 9.07 ± 2.30, 10.75 ± 3.49, and 19.80 ± 3.26 days, for each group, respectively. When comparing the DXR concentration in the heart tissues, the Lip-DXR-administered mice showed significantly lower DXR accumulation in the cardiac tissues after 1 and 12 hours than the DXR-administered mice.
Conclusion:
This study proved that liposome-infused DXR could be used effectively on murine neuroblastoma (C-1300 tumor cell model) and may reduce the incidence of cardiac toxicity as compared with DXR alone.